- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Schick delisted from Nasdaq
Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schick’s common stock would no longer be
Schick Technologies has been delisted from the Nasdaq stock exchange, the company has reported. On Sept. 15, Schick received notice from the Nasdaq Listing Qualifications Panel that as of close of business, Schicks common stock would no longer be traded on the exchange. The panel attributed its decision to Schicks inability to file its 10-K for fiscal 1999 (end-March) on time, as well as factors discussed in Schicks 8-K, filed on Sept. 2.
Schick will request a review of the panels decision within the 15-day limit required by Nasdaqs marketplace rules, and plans to file its 10-K and its 10-Q for the quarter ended June 30 as soon as the firms new accountants, Grant Thornton, complete their audit of Schicks financial statements. Schicks former accounting firm, PricewaterhouseCoopers, resigned as the companys independent accountants on Aug. 25. Schick will seek relisting on the exchange, or apply for listing on another exchange, once its filings are current with the Securities and Exchange Commission, according to the Long Island City, NY-based company.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
